What can biologic treatment do for patients with CRS with nasal polyps?

When Claus Bachert, M.D., Ph.D., says “the patient is king,” what does that mean for his approach to treating CRS with nasal polyps? Watch as the editor of The Journal of Allergy and Clinical Immunology explains what access to biologics like Dupixent means for his patients and his practice.

Easier access to biologics like Dupixent would allow more patients to receive treatment that targets the underlying source of CRS with nasal polyps.^1-3